Pulmonary Embolism (Diagnosis)NCT07023705
MLPR As A Diagnostic Marker For Acute Pulmonary Embolism
An observational study of Pulmonary Embolism (Diagnosis) and Diagnosis, run by Ain Shams University at 1 site in Egypt.
Trial summary
A retrospective study to assess the utility of hematological marker (monocyte to large platelet ratio) to diagnose patients with pulmonary embolism Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Pulmonary Embolism (Diagnosis), Diagnosis
- What is being tested?
- Monocyte to Large Platelet Ratio (MLPR)
- How many people
- 53 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jan 2024to 31 May 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients presenting to the emergency department with signs and symptoms of pulmonary embolism who underwent CT pulmonary angiography for diagnosis.
Who may be able to join
- Only patients with the results of full blood count and white blood cell differentiation, measured before the treatment of suspected PE.
- Patients underwent CT pulmonary angiography to confirm or exclude pulmonary embolism diagnosis.
Who cannot join
- Patient with history of any myeloproliferative disorder, myelofibrosis, Glanzmann thrombasthenia, May-Hegglin anomaly, Bernard-Soulier syndrome, suspicion of disseminated intravascular coagulation.
- Patient receiving any anticoagulant drug at a therapeutic dose.
- Patient with blood transfusion in the last 2 months.
- Patients with acute coronary syndrome, pulmonary edema.
- Patient on immunosuppressive drugs , Oral contraceptive pills .
- Patients with severe renal or hepatic disease.
- Patients with Stroke.
- Patients with malignancy.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Monocyte To Large Platelet Ratio As A Diagnostic Marker For Acute Pulmonary Embolism
A retrospective study to assess the utility of hematological marker (monocyte to large platelet ratio) to diagnose patients with pulmonary embolism
Read the detailed description
The investigators conducted a retrospective review of emergency department records of patients who presented with signs and symptoms suggestive of pulmonary embolism (PE) and underwent CT pulmonary angiography (CTPA) for diagnosis. Hematological laboratory findings obtained prior to any treatment were collected and compared between two groups based on CTPA results: those with confirmed PE (CT positive) and those without PE (CT negative).
- Conditions
- Pulmonary Embolism (Diagnosis), Diagnosis
- Being tested
- Monocyte to Large Platelet Ratio (MLPR)
- Medical subject headings
- Pulmonary Embolism, Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Monocyte to Large Platelet Ratio (MLPR)Diagnostic test
Admission laboratory values were used to calculate the Monocyte-to-Large Platelet Ratio (MLPR) by dividing the absolute monocyte count by the large platelet count. These values were obtained from blood samples collected before any treatment was administered.
| Study group | Role | What they receive |
|---|---|---|
| Pulmonary embolism | Group that is confirmed to have pulmonary embolism by positive CTPA finding filling defect. Receives: Diagnostic Test: Monocyte to Large Platelet Ratio (MLPR) | |
| Non-Pulmonary embolism | Group that have pulmonary embolism diagnosis was excluded by negative CTPA finding. Receives: Diagnostic Test: Monocyte to Large Platelet Ratio (MLPR) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Monocyte-to-Large Platelet Ratio (MLPR)
A ratio between monocyte absolute count and the large platelets count (MLPR) values compared between groups using Mann-Whitney U test; diagnostic accuracy evaluated by area under the curve (AUC) , sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).
Measured: At emergency department admission (baseline lab measurement) before any treatment.
Secondary outcomes (5)
Mean platelet volume (MPV)
MPV values compared between groups using Mann-Whitney U test; diagnostic accuracy evaluated by AUC, sensitivity, specificity, PPV, and NPV.
Measured: At emergency department admission (baseline lab measurement) before any treatment.
Neutrophil to Lymphocyte Ratio (NLR)
The ratio between absolute neutrophil and absolute lymphocytes count (NLR) values compared between groups using Mann-Whitney U test; diagnostic accuracy evaluated by AUC, sensitivity, specificity, PPV, and NPV.
Measured: At emergency department admission (baseline lab measurement) before any treatment.
D-Dimer Levels
D-Dimer concentration values compared between groups using Mann-Whitney U test; diagnostic accuracy evaluated by AUC, sensitivity, specificity, PPV, and NPV.
Measured: At emergency department admission (baseline lab measurement) before any treatment.
Platelet Distribution Width (PDW)
PDW values compared between groups using Mann-Whitney U test; diagnostic accuracy evaluated by AUC, sensitivity, specificity, PPV, and NPV.
Measured: At emergency department admission (baseline lab measurement) before any treatment.
Platelet To Lymphocyte Ratio (PLR)
The ratio between total platelets count and absolute lymphocytes count (PLR) values compared between groups using Mann-Whitney U test; diagnostic accuracy evaluated by AUC, sensitivity, specificity, PPV, and NPV.
Measured: At emergency department admission (baseline lab measurement) before any treatment.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jun 2025
- Study start1 Jan 2024
- Primary completion31 Dec 2024
- Study completion31 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Pulmonary Embolism (Diagnosis)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 53 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ain Shams University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohamed Kheder Aly Awad, Ain Shams University
- Investigators
- Reem H Elkabarity, Professor, Study chair, Ain Shams UniversityHadil M Abdelhamid, Professor, Study director, Ain Shams UniversityAzza Lotfy, Professor, Study director, Ain Shams UniversityMohamed k Awad, Lecturer, Principal investigator, Ain Shams University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07023705
- Sponsor's protocol ID
- FMASU MLPR 286
- Status last verified
- May 2026
- First submitted
- 9 Jun 2025
- Last updated
- 29 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Granger V, Faille D, Marani V, Noel B, Gallais Y, Szely N, Flament H, Pallardy M, Chollet-Martin S, de Chaisemartin L. Human blood monocytes are able to form extracellular traps. J Leukoc Biol. 2017 Sep;102(3):775-781. doi: 10.1189/jlb.3MA0916-411R. Epub 2017 May 2.
PubMed 28465447Moharamzadeh P, Rahmani F, Foroughifar S, Shahsavarinia K. Reliability of Platelet Indices for Diagnosing Pulmonary Embolism; a Brief Report. Adv J Emerg Med. 2019 Apr 28;3(3):e27. doi: 10.22114/ajem.v0i0.137. eCollection 2019 Summer.
PubMed 31410404Talay F, Ocak T, Alcelik A, Erkuran K, Akkaya A, Duran A, Demirhan A, Kar Kurt O, Asuk Z. A new diagnostic marker for acute pulmonary embolism in emergency department: mean platelet volume. Afr Health Sci. 2014 Mar;14(1):94-9. doi: 10.4314/ahs.v14i1.15.
PubMed 26060464Bialas AJ, Kornicki K, Ciebiada M, Antczak A, Sitarek P, Milkowska-Dymanowska J, Piotrowski WJ, Gorski P. Monocyte to large platelet ratio as a diagnostic tool for pulmonary embolism in patients with acute exacerbation of chronic obstructive pulmonary disease. Pol Arch Intern Med. 2018 Jan 31;128(1):15-23. doi: 10.20452/pamw.4141. Epub 2017 Nov 7.
PubMed 29112185
Study at a glance
From the registry record, last updated by the sponsor on 29 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Monocyte To Large Platelet Ratio As A Diagnostic Marker For Acute Pulmonary Embolism
- ClinicalTrials.gov ID
- NCT07023705
- Acronym / sponsor ID
- FMASU MLPR 286
- Conditions
- Pulmonary Embolism (Diagnosis), Diagnosis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 53 participants (actual)
- Lead sponsor
- Ain Shams UniversityUniversity, hospital or other
- Study start
- 1 Jan 2024 (actual)
- Primary completion
- 31 Dec 2024 (actual)
- Study completion
- 31 May 2025 (actual)
- First posted
- 17 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A retrospective study to assess the utility of hematological marker (monocyte to large platelet ratio) to diagnose patients with pulmonary embolism
Detailed description
The investigators conducted a retrospective review of emergency department records of patients who presented with signs and symptoms suggestive of pulmonary embolism (PE) and underwent CT pulmonary angiography (CTPA) for diagnosis. Hematological laboratory findings obtained prior to any treatment were collected and compared between two groups based on CTPA results: those with confirmed PE (CT positive) and those without PE (CT negative).
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Pulmonary embolism | – | Diagnostic Test: Monocyte to Large Platelet Ratio (MLPR)Group that is confirmed to have pulmonary embolism by positive CTPA finding filling defect. |
| Non-Pulmonary embolism | – | Diagnostic Test: Monocyte to Large Platelet Ratio (MLPR)Group that have pulmonary embolism diagnosis was excluded by negative CTPA finding. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients presenting to the emergency department with signs and symptoms of pulmonary embolism who underwent CT pulmonary angiography for diagnosis.
Key inclusion criteria (2 listed)
- Only patients with the results of full blood count and white blood cell differentiation, measured before the treatment of suspected PE.
- Patients underwent CT pulmonary angiography to confirm or exclude pulmonary embolism diagnosis.
Key exclusion criteria (8 listed)
- Patient with history of any myeloproliferative disorder, myelofibrosis, Glanzmann thrombasthenia, May-Hegglin anomaly, Bernard-Soulier syndrome, suspicion of disseminated intravascular coagulation.
- Patient receiving any anticoagulant drug at a therapeutic dose.
- Patient with blood transfusion in the last 2 months.
- Patients with acute coronary syndrome, pulmonary edema.
- Patient on immunosuppressive drugs , Oral contraceptive pills .
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Monocyte to Large Platelet Ratio (MLPR)Admission laboratory values were used to calculate the Monocyte-to-Large Platelet Ratio (MLPR) by dividing the absolute monocyte count by the large platelet count. These values were obtained from blood samples collected before any treatment was administered. | Diagnostic test | Non-Pulmonary embolism, Pulmonary embolism |
Primary outcome
Monocyte-to-Large Platelet Ratio (MLPR)
Time frame: At emergency department admission (baseline lab measurement) before any treatment.
A ratio between monocyte absolute count and the large platelets count (MLPR) values compared between groups using Mann-Whitney U test; diagnostic accuracy evaluated by area under the curve (AUC) , sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).
5 secondary outcomes
Mean platelet volume (MPV)
Time frame: At emergency department admission (baseline lab measurement) before any treatment.
Neutrophil to Lymphocyte Ratio (NLR)
Time frame: At emergency department admission (baseline lab measurement) before any treatment.
D-Dimer Levels
Time frame: At emergency department admission (baseline lab measurement) before any treatment.
Platelet Distribution Width (PDW)
Time frame: At emergency department admission (baseline lab measurement) before any treatment.
Platelet To Lymphocyte Ratio (PLR)
Time frame: At emergency department admission (baseline lab measurement) before any treatment.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 May 2026.
- Background: PubMed 28465447Granger V, Faille D, Marani V, Noel B, Gallais Y, Szely N, Flament H, Pallardy M, Chollet-Martin S, de Chaisemartin L. Human blood monocytes are able to form extracellular traps. J Leukoc Biol. 2017 Sep;102(3):775-781. doi: 10.1189/jlb.3MA0916-411R. Epub 2017 May 2.
- Background: PubMed 31410404Moharamzadeh P, Rahmani F, Foroughifar S, Shahsavarinia K. Reliability of Platelet Indices for Diagnosing Pulmonary Embolism; a Brief Report. Adv J Emerg Med. 2019 Apr 28;3(3):e27. doi: 10.22114/ajem.v0i0.137. eCollection 2019 Summer.
- Background: PubMed 26060464Talay F, Ocak T, Alcelik A, Erkuran K, Akkaya A, Duran A, Demirhan A, Kar Kurt O, Asuk Z. A new diagnostic marker for acute pulmonary embolism in emergency department: mean platelet volume. Afr Health Sci. 2014 Mar;14(1):94-9. doi: 10.4314/ahs.v14i1.15.
- Results publication: PubMed 29112185Bialas AJ, Kornicki K, Ciebiada M, Antczak A, Sitarek P, Milkowska-Dymanowska J, Piotrowski WJ, Gorski P. Monocyte to large platelet ratio as a diagnostic tool for pulmonary embolism in patients with acute exacerbation of chronic obstructive pulmonary disease. Pol Arch Intern Med. 2018 Jan 31;128(1):15-23. doi: 10.20452/pamw.4141. Epub 2017 Nov 7.
- Individual participant dataSharing planned: No
Related trials for Pulmonary Embolism (Diagnosis)
RecruitingObservational study
Clinical Management and Outcomes After Lung Scintigraphy for Suspected Pulmonary Embolism in the Emergency Department
Pulmonary Embolism (Diagnosis)
Not yet recruiting
CTEPH Differential Diagnosis Assisted by Enhanced Large Language Model Support
Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Acute Pulmonary Embolism (PE)
Active, not recruitingPhase 3
Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy
Pulmonary Embolism
Not yet recruiting
Exclusion of Left Atrial Appendage Thrombus in Emergency Department Patients With Atrial Fibrillation Undergoing CT to Assess for Pulmonary Embolus: A Feasibility Study
Atrial Fibrillation (AF), Pulmonary Embolism (PE)
Not yet recruitingPhase 2
Phase IIA Study of Belzutifan in EPAS1-, EGLN1-, or VHL-Mutant Erythrocytosis
Erythrocytosis, Pulmonary Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Reem H Elkabarity, Professor study chair
Ain Shams University
Hadil M Abdelhamid, Professor study director
Ain Shams University
Azza Lotfy, Professor study director
Ain Shams University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pulmonary Embolism (Diagnosis) and Diagnosis, run by Ain Shams University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Monocyte-to-Large Platelet Ratio (MLPR) (time frame: At emergency department admission (baseline lab measurement) before any treatment.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07023705, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 May 2026.